RESUMEN
A bioanalytical LC-MS/MS method was developed and validated for the simultaneous quantification of capsaicin (CAPS) and dihydrocapsaicin (D-CAPS) in dermal microdialysis samples from rats. Capsaicinoids were separated by using a C18 column, with a mobile phase of water and acetonitrile, both with 0.1% of formic acid, eluted as a gradient. Compounds were detected by using an electrospray ionization source operating in the positive mode (ESI+) to monitor the m/z transitions of 306.1â¯>â¯137.0 for CAPS and 308.1â¯>â¯137.0 for D-CAPS. The method showed linearity in the concentration range of 0.5-100â¯ng/ml for CAPS and 0.25-100â¯ng/ml for D-CAPS, with coefficients of determination of ≥ 0.99. The inter- and intra-day precision, accuracy, and compound stability in different conditions were in accordance with the limits established by the US Food and Drug Administration guidelines. The recovery of the drugs by microdialysis were dependent on the flow rate, but independent of drug concentration. For CAPS, calibration of the in vitro microdialysis probes by dialysis and retrodialysis resulted in statistically similar drug recovery of 68.5% ± 5.9% and 77.8% ± 6.6%, respectively, at a flow rate of 0.5 µl/min. For D-CAPS, the recovery by dialysis was lower than by retrodialysis, at 51.4% ± 6.6% and 92.6% ± 2.4%, respectively. This difference was attributed to the binding of D-CAPS to the plastic tubing, which was experimentally evaluated and mathematically modeled. In vivo recoveries were 75.7% ± 6.3% for CAPS and 81.9% ± 1.5% for D-CAPS at the same flow rate. The analytical method showed high specificity, accuracy, and sensitivity, and suitability for dermatopharmacokinetic studies. These results will allow the determination of the actual free concentration of these drugs in dermatopharmacokinetic experiments, as shown in a pilot experiment with a commercial cream containing capsaicinoids.
Asunto(s)
Capsaicina/análogos & derivados , Capsaicina/análisis , Fármacos del Sistema Sensorial/análisis , Crema para la Piel/análisis , Animales , Capsaicina/administración & dosificación , Capsaicina/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Dermis/química , Masculino , Microdiálisis/métodos , Modelos Animales , Ratas , Ratas Wistar , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Fármacos del Sistema Sensorial/administración & dosificación , Fármacos del Sistema Sensorial/farmacocinética , Crema para la Piel/administración & dosificación , Crema para la Piel/farmacocinética , Espectrometría de Masas en Tándem/métodos , Distribución TisularRESUMEN
Opioid receptors are localized throughout peripheral and central nervous system and interact with endogenous opioid peptides and drugs including heroin, synthetic opioids, and pain relievers (codeine, morphine). If several opioid PET tracers exist for preclinical studies, only a few have been used in human. Some tracers are selective for one subtype of opioid receptors (e.g., [11C]CAF (carfentanil) for µ receptor) while others are not ([11C]DPN (diprenorphine)). As shown by imaging studies, the opioid system is involved in pain processing, but also in addiction, neuropsychiatric manifestations (harm avoidance, sadness, novelty seeking behavior), feeding and food disorders and, finally, movement disorders and levodopa-induced dyskinesias. However, no imaging study has analyzed the potential dysfunction of opioid system in pain manifestations in Parkinson's disease. In addition, the involvement of opioid system in impulse control disorders and neuropsychiatric manifestations has never been studied in Parkinson's disease. Thus, there is an urgent need to understand the impact of opioid system dysfunctions in Parkinson's disease.
Asunto(s)
Síntomas Conductuales , Trastornos Disruptivos, del Control de Impulso y de la Conducta , Trastornos de Alimentación y de la Ingestión de Alimentos , Imagen Molecular/métodos , Dolor , Enfermedad de Parkinson , Tomografía de Emisión de Positrones/métodos , Receptores Opioides/metabolismo , Fármacos del Sistema Sensorial/farmacocinética , Síntomas Conductuales/diagnóstico por imagen , Síntomas Conductuales/metabolismo , Trastornos Disruptivos, del Control de Impulso y de la Conducta/diagnóstico por imagen , Trastornos Disruptivos, del Control de Impulso y de la Conducta/etiología , Trastornos Disruptivos, del Control de Impulso y de la Conducta/metabolismo , Trastornos de Alimentación y de la Ingestión de Alimentos/diagnóstico por imagen , Trastornos de Alimentación y de la Ingestión de Alimentos/etiología , Trastornos de Alimentación y de la Ingestión de Alimentos/metabolismo , Humanos , Dolor/diagnóstico por imagen , Dolor/etiología , Dolor/metabolismo , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/diagnóstico por imagen , Enfermedad de Parkinson/metabolismoRESUMEN
Skin diseases are usually treated using topical formulations. Frequently, multiple applications per day are necessary, as up to 90% of the formulation (and thus of the active) are withdrawn from the skin by contact with the environment. During the development of topical formulations ex vivo permeation and penetration experiments are deployed to characterize the formulations. Still, these tests do not take into account the removal of formulations during the application period. To date, only few methods exist to probe the substantivity of dermal formulations. The aim of this investigation was to develop methods that simulate skin-to-skin or clothing-to-skin contact and enable the determination of the amount of formulation that is removed from the skin due to the contact. Three different types of formulations were used to validate the systems: a conventional semisolid cream, an oil-in-oil-emulsion, and a film forming formulation. The results showed that the substantivity decreased in the order: film forming formulation > semisolid cream > oil-in-oil-emulsion. A similar trend could be determined with both methods although the total amounts of withdrawn formulation differed. The developed methods can add to the knowledge about the formulation and can be used to develop formulations that exhibit higher substantivity.
Asunto(s)
Capsaicina/análogos & derivados , Preparaciones de Acción Retardada/química , Emulsiones/química , Aceites/química , Fármacos del Sistema Sensorial/administración & dosificación , Absorción Cutánea , Crema para la Piel/química , Administración Cutánea , Animales , Capsaicina/administración & dosificación , Capsaicina/farmacocinética , Composición de Medicamentos/métodos , Fármacos del Sistema Sensorial/farmacocinética , Piel/metabolismo , PorcinosRESUMEN
The capsaicin 8 % patch (QUTENZA®) is an adhesive patch containing a high concentration (8 % w/w) of synthetic capsaicin, a selective agonist of transient receptor potential vanilloid 1 channel. It is approved for treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain in the EU; it is only approved to treat postherpetic neuralgia (PHN) in the USA. In patients with painful diabetic peripheral neuropathy (PDPN), a single 30-min application of the capsaicin 8 % patch significantly improved pain relief and sleep quality compared with placebo in a 12-week double-blind trial. In a 52-week, randomized trial, up to seven consecutive 30-min treatments with the capsaicin 8 % patch (≤7 treatments each at least 8 weeks apart) plus standard of care therapy was associated with sustained pain relief and no negative neurological safety consequences compared with standard of care. In two randomized trials, a single 60-min application of the capsaicin 8 % patch reduced pain scores significantly more than a low-concentration (0.04 %) capsaicin control patch in patients with PHN. Capsaicin 8 % patch treatment was noninferior to pregabalin (optimized dosage) in a randomized trial in patients with nondiabetic peripheral neuropathic pain. Results in two trials in patients with HIV-AN were equivocal, with a significant improvement in pain intensity observed in one trial, but not in the other. The capsaicin 8 % patch was associated with expected, transient, capsaicin-related application-site adverse events such as erythema and pain.
Asunto(s)
Capsaicina/administración & dosificación , Capsaicina/uso terapéutico , Neuropatías Diabéticas/tratamiento farmacológico , Neuralgia Posherpética/tratamiento farmacológico , Enfermedades del Sistema Nervioso Periférico/tratamiento farmacológico , Parche Transdérmico , Capsaicina/efectos adversos , Capsaicina/farmacocinética , Humanos , Manejo del Dolor , Pregabalina/uso terapéutico , Fármacos del Sistema Sensorial/efectos adversos , Fármacos del Sistema Sensorial/farmacocinética , Fármacos del Sistema Sensorial/farmacología , Fármacos del Sistema Sensorial/uso terapéutico , Parche Transdérmico/efectos adversosRESUMEN
The use of nanotechnology is increasing exponentially, whereas the possible adverse health effects of engineered nanoparticles (NPs) are so far less known. Standardized mouse bioassay was used to study sensory and pulmonary irritation, airflow limitation, and inflammation potency of nanosized TiO(2). Single exposure (0.5 h) to in situ generated TiO(2) (primary particle size 20 nm; geometric mean diameters of 91, 113, and 130 nm at mass concentrations of 8, 20, and 30 mg/m(3), respectively; crystal phase anatase + brookite (3:1)) caused airflow limitation in the conducting airways at each studied exposure concentration, which was shown as a reduction in expiratory flow, being at the lowest 73% of baseline. The response was not dose dependent. Repeated exposures (altogether 16 h, 1 h/day, 4 days/week for 4 weeks) to TiO(2) at mass concentration of 30 mg/m(3) caused as intense airflow limitation effect as the single exposures, and the extent of the responses stayed about the same along the exposure days. Sensory irritation was fairly minor. Pulmonary irritation was more pronounced during the latter part of the repeated exposures compared to the single exposures and the beginning of the repeated exposures. Sensory and pulmonary irritation were observed also in the control group, and, therefore, reaction by-products (NO(2) and C(3)H(6)) may have contributed to the irritation effects. TiO(2) NPs accumulated mainly in the pulmonary macrophages, and they did not cause nasal or pulmonary inflammation. In conclusion, the irritation and inflammation potencies of studied TiO(2) seemed to be low.
Asunto(s)
Irritantes/toxicidad , Nanopartículas del Metal/toxicidad , Ventilación Pulmonar/efectos de los fármacos , Sistema Respiratorio/efectos de los fármacos , Fármacos del Sistema Sensorial/toxicidad , Titanio/toxicidad , Aerosoles , Alquenos/metabolismo , Animales , Animales no Consanguíneos , Monóxido de Carbono/metabolismo , Permeabilidad de la Membrana Celular , Relación Dosis-Respuesta a Droga , Concentración de Iones de Hidrógeno , Irritantes/administración & dosificación , Irritantes/química , Irritantes/farmacocinética , Macrófagos Alveolares/química , Macrófagos Alveolares/efectos de los fármacos , Macrófagos Alveolares/inmunología , Macrófagos Alveolares/ultraestructura , Masculino , Ensayo de Materiales , Nanopartículas del Metal/administración & dosificación , Nanopartículas del Metal/química , Ratones , Óxido Nítrico/metabolismo , Tamaño de la Partícula , Sistema Respiratorio/inmunología , Sistema Respiratorio/metabolismo , Sistema Respiratorio/ultraestructura , Fármacos del Sistema Sensorial/administración & dosificación , Fármacos del Sistema Sensorial/química , Fármacos del Sistema Sensorial/farmacocinética , Titanio/administración & dosificación , Titanio/química , Titanio/farmacocinéticaRESUMEN
Despite currently available treatments, postherpetic neuralgia continues to be a challenging pain condition to treat. Many patients remain in pain or suffer side effects from the (combination) therapies. A patch containing 8% capsaicin (research code NGX-4010 and marketed under the trade name Qutenza(®)), approved both in the EU and USA, provides a localized therapy with effects lasting up to 12 weeks after a single 60-min application. This review will summarize clinical trial evidence on the safety, efficacy and unique attributes of this capsaicin 8% patch in the treatment of postherpetic neuralgia. The action of capsaicin on the transient receptor potential cation channel, subfamily V, member 1 receptors will be discussed.
Asunto(s)
Capsaicina/administración & dosificación , Neuralgia Posherpética/tratamiento farmacológico , Fármacos del Sistema Sensorial/administración & dosificación , Administración Cutánea , Capsaicina/efectos adversos , Capsaicina/química , Capsaicina/farmacocinética , Ensayos Clínicos como Asunto , Europa (Continente) , Humanos , Fármacos del Sistema Sensorial/efectos adversos , Fármacos del Sistema Sensorial/química , Fármacos del Sistema Sensorial/farmacocinética , Canales Catiónicos TRPV/metabolismo , Parche Transdérmico , Estados UnidosRESUMEN
IMPORTANCE OF THE FIELD: Capsaicin and its receptor, TRPV1, occupy a central place in current neurophysiological studies regarding pain transmission and have opened new avenues for understanding the role of transient receptor potential (TRP) receptors in itch processing. Substantial efforts in drug discovery are at present directed at vanilloid receptors for finding new remedies for pain and itch. AREAS COVERED IN THIS REVIEW: We provide an overview of the major clinical indications of capsaicin, primarily targeting pain and itch of various origins, with an emphasis on the usefulness of capsaicin in treating pruritus and dermatological conditions. In particular, we cover the most relevant findings in recent years, from 2000 onward (although seminal discoveries and studies are discussed irrespective of their date of publication if deemed essential for understanding capsaicin's actions). WHAT THE READER WILL GAIN: Readers are offered a broad perspective on the areas of clinical application of capsaicin, emphasizing its usefulness in the treatment of neurophatic pain and pruritus of various origins. TAKE HOME MESSAGE: Capsaicin has been proven a truly exciting molecule and remains a valuable drug for alleviating pain and itch, widely surpassing its role as a simple spicy ingredient.